Opinion|Videos|December 28, 2023
Amivantamab in EGFR Exon 20 Insertion Mutated NSCLC Progression on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase 1 Study
Dr. Herbst discusses the CHRYSALIS Phase 1 trial.
Advertisement
Episodes in this series
Advertisement
Related to this article
Lisa Carter-Bawa, PhD, APRN, discusses policy barriers, arts-based outreach, AI, and stigma in lung cancer screening.
Immune checkpoint inhibitors have reshaped treatment for extensive-stage small cell lung cancer, though their role in limited-stage disease remains uncertain.
Training AI on data without good representation of underserved populations may unintentionally widen disparities in lung cancer care.
At the BIG10 CRC Summit, Mingjia Li, MD, outlined how pre-operative hemoglobin may signal treatment response in resectable NSCLC.
Advertisement
Advertisement
Trending on CancerNetwork
1
The Gynecologic Oncology Data to Watch at ESMO 2026: De-Escalation and ADCs
2
Monitoring Anemia and Optimizing Regimen Selection in Resectable NSCLC
3
The Usefulness of Indocyanine Green in Cytoreductive Ovarian Cancer Surgery
4
Cancer Vaccine Combinations Improve 1-Year Survival in Second-Line NSCLC
5